CuroNZ
Major Drugs - N/A, N/A, NZ
CuroNZ Employees
CuroNZ Senior Management
CuroNZ Details
CuroNZ is a Biotechnology company with exclusive rights over the patent portfolio of Neural Regeneration Peptides (NRPs) of which, one of the company's Directors, Dr Frank Sieg, was the principal inventor. We have completed Phase I Clinical development with pristine safety in healthy volunteers. Our lead compound NRP2945 is in development for the orphan indication Lennox-Gastaut Syndrome (a sever form of childhood epilepsy). We will conduct a Phase II study in children in 2022. NRPs have the potential to be a high impact drug as they work on a unique MOA and are neuroregenerative as well as neuroprotective. In addition to our lead compound we are working on a follow up compound that will be developed for other CNS diseases. We have data showing NRPs have memory enhancing capabilities. In April 2021 we were awarded Orphan drug status for LGS. Our aim is to license the technology or find partners that will enable us to take it to market.
CuroNZ Technologies
Email Providers
Outlook
Other
Microsoft Office 365